景峰医药(000908) - 2024 Q4 - 年度业绩预告

Financial Performance Expectations - The company expects a total profit of between 12,000.00 million and 16,000.00 million CNY for the fiscal year 2024, compared to a loss of 19,462.16 million CNY in the same period last year[3] - The net profit attributable to shareholders is projected to be between 11,000.00 million and 16,000.00 million CNY, compared to a loss of 23,610.04 million CNY in the previous year[3] - The operating revenue is estimated to be between 38,000.00 million and 42,000.00 million CNY, down from 65,689.38 million CNY in the same period last year[3] - The company's net assets are expected to turn positive, with an estimated range of 58,000.00 million to 87,000.00 million CNY at the end of the fiscal year, compared to a negative 7,045.08 million CNY at the end of the previous year[3] Debt and Financial Obligations - The company has signed a debt waiver agreement with five fund managers, resulting in a total waiver of 110 million CNY in principal and an estimated impact of 250 million to 270 million CNY on investment income, which is classified as non-recurring gains and losses[5] - The company has not yet repaid the principal of 295 million CNY for the "16 Jingfeng 01" bond, and the remaining unpaid principal after the debt waiver is 185 million CNY[12] Risks and Uncertainties - The company faces risks of being delisted if it fails to meet certain financial criteria, including a negative net profit or net assets[7] - There is significant uncertainty regarding the company's ability to continue as a going concern, as the net profit for the last three fiscal years is expected to be negative[9] - The company is currently in a pre-restructuring process, with uncertainties surrounding its ability to enter formal restructuring proceedings[10] Disclosure and Reporting - The financial data presented is preliminary and subject to audit, with detailed financial results to be disclosed in the 2024 annual report[13] - The company has selected information disclosure media including "China Securities Journal," "Securities Times," "Shanghai Securities Journal," "Securities Daily," and the Giant Tide Information Network[14] - The announcement was made by the board of directors of Hunan Jingfeng Pharmaceutical Co., Ltd. on January 22, 2025[15]